HNSBF - Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript
2025-02-06 13:13:06 ET
Hansa Biopharma AB (HNSBF)
Q4 2024 Earnings Conference Call
February 6, 2025 08:00 AM ET
Company Participants
Soren Tulstrup - President and CEO
Evan Ballantyne - Chief Financial Officer
Hitto Kaufmann - Chief R&D Officer
Conference Call Participants
Suzanne van Voorthuizen - Kempen
Alexander Kramer - ABG
Douglas Tsao - H.C. Wainwright
Eric Young - William Blair
Johan Unnerus – Redeye
Presentation
Operator
Good day, and welcome to the Hansa Biopharma Year End and Fourth Quarter 2024 Report. All participants will be in listen-only mode. [Operator Instructions] After today’ s presentation there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Soren Tulstrup, President and CEO. Please go ahead.
Soren Tulstrup
Thank you, operator. Good afternoon, good morning, and welcome to the Hansa Biopharma conference call to review the full-year and Q4 results for 2024. I'm John Tulloch, President and CEO of Hansa Biopharma. Joining me today is Evan Ballanti-ne, Chief Financial Officer and Hitto Kaufmann, Chief R&D Officer.
Please turn to Slide 2. Please allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution....
Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript